MCLA-129
1 product
3 abstracts
2 targets
Target
c-Met proteinTarget
EGFR mutationAbstract
Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-MET exon 14 skipping mutations (METex14).Org: Department of Pulmonology, Department of Early Clinical Trials, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology,
Abstract
Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC).Org: Thoracic Medicine Department 2, The Affiliated Cancer Hospital of Xiangya School of Medicine and Hunan Cancer Hospital, Central South University, Changsha, China, First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, China, Tianjin Cancer Institute and Hospital, Tianjin, China, Department of Medical Oncology, The First Hospital of Lanzhou University, Lanzhou, China, Department of Oncology and Hematology, China-Japan Union Hospital of Jilin University, Changchun, China,
Abstract
Impact of neighborhood deprivation on disability free survival in patients with aggressive B cell non-Hodgkin lymphoma.Org: Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, Feinberg School of Medicine, Northwestern University, Northwestern University Feinberg School of Medicine,
Product
MCLA-129